Matthew S. Lawrence, M.D., Ph.D.

Chief Executive Officer & Chief Scientific Officer, Co-Founder

Dr. Lawrence is responsible for directing the company’s research activities and guiding and prioritizing scientific initiatives. In this capacity he coordinates scientific interactions with collaborating investigators and sponsoring institutions and oversees strategic planning to meet study objectives. He was recruited to this position for his unique research and clinical background, and over twenty years experience working at the primate research facility. Prior to joining RxGen, Dr. Lawrence completed an ophthalmology residency at the Massachusetts Eye and Ear Infirmary, an internal medicine residency at the University of Hawaii, and a medical degree at Yale. After completing a BA in biology and geology at Harvard, Dr. Lawrence received a Ph.D. in Neuroscience at Stanford University, conducting research related to in vitro and in vivo gene delivery and neuronal injury. Following his doctoral work and through his subsequent career Dr. Lawrence has continued to work in the fields of gene therapy, neurodegenerative disease, ophthalmology and metabolism. He has been awarded multiple small business innovation research (SBIR) grants and holds an adjunct position in the Section of Comparative Medicine at Yale School of Medicine

Christopher M. Stanley

Vice-President & Chief Business Officer, Co-Founder

Mr. Stanley has broad responsibility for RxGen’s business strategy, business and corporate development, and finance activities.   Mr. Stanley has been instrumental in identifying and negotiating academic and industry partnerships, contract research agreements, and collaboration agreements to advance a variety of therapeutic and drug delivery technology development initiatives.  Prior to joining RxGen, Mr. Stanley was at Accenture, LLP where he managed business development, financial planning and corporate transaction activities related to venture and strategic investments and cross-border outsourcing transactions in the Corporate Transactions Group.  At Accenture, Mr. Stanley’s primary responsibilities included business case development, investment memorandum development, overseeing due diligence, business and financial modeling, and developing valuation and capitalization models in support of a wide range of investment opportunities and client engagements ranging from technology startups to Fortune 1000 companies.  Prior to Accenture, Mr. Stanley worked in Global Markets for Chase Manhattan Bank supporting the fixed-income and derivative securities trading desk.  Mr. Stanley holds a degree (BBA) in Finance from The University of Texas at Austin.